Cited by 1243D Printing in Biomedical ResearchTissue Engineering and Regenerative MedicineMicrofluidic and Capillary Electrophoresis Applications

Progress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models

Open access
Wnorowski, Alexa, Yang, Huaxiao, Wu, Joseph C.·2019·Advanced Drug Delivery Reviews

Abstract

In recent years, drug development costs have soared, primarily due to the failure of preclinical animal and cell culture models, which do not directly translate to human physiology. Organ-on-a-chip (OOC) is a burgeoning technology with the potential to revolutionize disease modeling, drug discovery, and toxicology research by strengthening the relevance of culture-based models while reducing costly animal studies. Although OOC models can incorporate a variety of tissue sources, the most robust and relevant OOC models going forward will include stem cells. In this review, we will highlight the benefits of stem cells as a tissue source while considering current limitations to their complete and effective implementation into OOC models.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.addr.2018.06.001

Cites

112 of 112 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Using hiPSCs offers advantages for patient-specific modeling, particularly in the context of genetic disorders, yet still faces the challenge of incomplete cellular maturation and differentiation variability.

    “Using hiPSCs offers advantages for patient-specific modeling, particularly in the context of genetic disorders, yet still faces the challenge of incomplete cellular maturation and differentiation variability (Wnorowski et al., 2019; Low et al., 2021; Devalla and Passier, 2018).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Wnorowski, A., Yang, H., & Wu, J. C.
Affiliations
  • Stanford Cardiovascular Institute (US)
  • Stanford Medicine (US)
Corresponding author
Wu, Joseph C.
Venue
Advanced Drug Delivery Reviews
Publisher
Elsevier BV
Published
2019-02
Volume
140
Pages
3-11
ISSN
0169-409X (ISSN-L)
OpenAlex
W2806689329
Cited by
124
References
112
Citations by year
2026: 11 · 2025: 16 · 2024: 26 · 2023: 16 · 2022: 16 · 2021: 17 · 2020: 11 · 2019: 11
FWCI
0.79
Type
journal article
Language
en
Open access
Locations
  • Advanced Drug Delivery Reviews (acceptedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Defense Science & Engineering Graduate
  • Stanford Cardiovascular Institute
  • Gooter Foundation (2017)
  • American Heart Association (18POST34030106)
  • National Institutes of Health (R01 HL1130020, R01 HL128170, R01 HL113006)
  • California Institute of Regenerative Medicine (DR2A-05394)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
Keywords
organ-on-a-chip, stem cells, disease modeling, drug discovery, toxicology, tissue engineering, alternatives to animal testing, preclinical models
MeSH terms
Animals, Humans, Stem Cells, Tissue Engineering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review